DOCETAXEL-INDUCED FEBRILE NEUTROPENIA IN BREAST CANCER PATIENTS IN MALAYSIA
https://doi.org/10.22452/jummec.vol25no1.1
- Author:
David Dai-Wee Lee
1
;
Fuad Ismail
2
Author Information
1. University Malaya Medical Center, Lembah Pantai, 59100 Kuala Lumpur, Malaysia.
2. Universiti Kebangsaan Malaysia Medical Center, Jalan Yaacob Latif, Bandar Tun Razak, 56000 Kuala Lumpur, Malaysia.
- Publication Type:Journal Article
- Keywords:
Advanced breast cancer;
Chemotherapy;
Docetaxel;
Febrile neutropenia
- MeSH:
Drug Therapy
- From:Journal of University of Malaya Medical Centre
2022;25(1):1-4
- CountryMalaysia
- Language:English
-
Abstract:
Docetaxel induced febrile neutropenia (FN) is a common adverse event encountered by breast cancer patients worldwide, especially among Asian patients. We aim to evaluate incidence of FN in breast cancer patients receiving docetaxel in Malaysia.
We retrospectively reviewed the records from patients with breast cancer who received docetaxel in a university-hospital. The incidence of FN, length of hospital stay, incidence of ICU admission, incidence and grade of neutropenia were evaluated.
Among 237 breast cancer patients, incidence of FN was 14.34% (34 patients). Mean length of hospital stay was 9.28 days (2 to 94 days). Two patients (0.84%) required admission to the ICU with the length of stay being 4 and 60 days respectively. Incidences of neutropenia are 27.8% (grade 1), 0.8% (grade 2), 1.69% (grade 3) and 0.4% (grade 4).
The incidence of febrile neutropenia due to docetaxel was higher among this population. This data may help to determine the optimal dose of docetaxel in breast cancer patients.
- Full text:202508131129056867780236.pdf
